Edinburgh Molecular Imaging (EMI), a spin-out of the Scottish capital’s university, has raised £4m ($6.5m) from venture firm Epidarex Capital.

The funding will be used to further develop EMI’s imaging technology, used to diagnose and monitor diseases. EMI’s current focus is on lung conditions such as cancer and fibrosis, but will eventually be expanded to include a wider range of diseases.

EMI, which was founded in 2011 and based at Edinburgh University’s bioquarter, aims to increase disease survival rates by…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?